FOLLICULAR LYMPHOMA TREATMENT IN
CHINA — INCLUDING CAR-T

Most patients with follicular lymphoma do not start by searching for a country. They start with a problem. The first treatment worked, but the disease came back. The second-line option is uncertain. The local oncologist has mentioned CAR-T or a clinical trial but cannot offer it directly. Cost has become a serious barrier, or a specific agent simply is not approved at home. China has built one of the largest CAR-T and cell therapy ecosystems in the world. Several CD19 CAR-T products are now approved for relapsed lymphoma, and many academic and specialist centres run trials specifically for follicular lymphoma, including products targeting CD19, CD20, CD22, and combinations. Bispecific antibodies that engage T cells, including mosunetuzumab-class agents, are also in active use within trial settings. Domestic Chinese pricing for several advanced therapies is significantly lower than equivalent options in the United States or Europe, which makes complex treatment plans more practical for international families. For follicular lymphoma specifically, China is relevant when the disease has relapsed early, when standard chemoimmunotherapy is no longer suitable, or when the family wants to explore CAR-T and bispecific options before committing to stem cell transplant.

Follicular lymphoma is a slow-growing B-cell non-Hodgkin lymphoma that arises from germinal centre B cells, most often carrying the BCL2 gene rearrangement t(14;18). It typically presents with painless lymph node enlargement, sometimes with bone marrow involvement, and is usually diagnosed at advanced stage even when symptoms are minimal. Pathologists grade follicular lymphoma from 1 to 3A based on the proportion of large cells, while grade 3B behaves more like diffuse large B-cell lymphoma and is treated differently. A key clinical concern is histologic transformation, where indolent follicular lymphoma converts into an aggressive lymphoma, usually DLBCL. This changes treatment strategy substantially. Most patients respond well to first-line therapy, but follicular lymphoma is generally considered incurable with current standard treatment. The pattern is typically remission, relapse, and re-treatment, with the goal of achieving long, good-quality remissions while preserving future options. Patients who relapse within 24 months of initial chemoimmunotherapy, called POD24, have worse outcomes and are usually considered for more intensive or novel approaches earlier.

First-Line Treatment Not every newly diagnosed patient needs immediate treatment. Many with low tumour burden and no symptoms are managed with active surveillance, sometimes for years. When treatment is needed, options include rituximab monotherapy for low-burden disease, or chemoimmunotherapy regimens such as bendamustine plus rituximab, R-CHOP, or R-CVP, often followed by rituximab maintenance. Obinutuzumab-based regimens are also used. Localised stage I disease may be treated with involved-site radiotherapy. Second-Line and Later Treatment When the disease relapses, the next regimen depends on what was given before, how long the remission lasted, and the patient's overall condition. Options include alternative chemoimmunotherapy, lenalidomide plus rituximab (R-squared), bispecific antibodies such as mosunetuzumab, EZH2 inhibitors such as tazemetostat, and PI3K-class drugs in selected settings. Stem cell transplantation, both autologous and allogeneic, remains an option for fit patients with chemo-sensitive relapse. CAR-T Cell Therapy CAR-T therapy uses the patient's own T cells, genetically modified to recognise the CD19 antigen on B-lymphoma cells. After leukapheresis, manufacturing, lymphodepleting chemotherapy, and infusion, the engineered cells expand and attack residual lymphoma. CAR-T has shown meaningful and sometimes durable responses in heavily pre-treated follicular lymphoma, including in POD24 patients. In China, CD19 CAR-T products are approved for relapsed or refractory large B-cell lymphoma and are increasingly used or trialled in follicular lymphoma. Several Chinese-developed CAR-T products and trial-stage cellular therapies, including dual-target and CAR-NK constructs, are accessible through specialist hospitals and registered clinical trials. Bispecific Antibodies Bispecific antibodies bind both a B-cell antigen and a T-cell receptor, bringing immune cells directly to the tumour. Mosunetuzumab and similar molecules have shown strong responses in relapsed follicular lymphoma and are an option in patients who cannot or do not wish to undergo CAR-T or transplant. Bispecific access in China is largely through approved use in selected indications and active clinical trials.

Eligibility is always reviewed by the treating hospital and depends on multiple factors: Patients with transformed follicular lymphoma are often evaluated under aggressive lymphoma protocols and may have access to a wider set of CAR-T products.

• Confirmed pathology of follicular lymphoma with grade clearl

  Confirmed pathology of follicular lymphoma with grade clearly stated

• CD19 or CD20 expression confirmed by IHC or flow cytometry,

  CD19 or CD20 expression confirmed by IHC or flow cytometry, depending on the planned product

• Relapsed or refractory disease, usually after at least two p

  Relapsed or refractory disease, usually after at least two prior lines of systemic therapy

• POD24 patients may be considered earlier in the treatment se

  POD24 patients may be considered earlier in the treatment sequence

• No clinically significant CNS lymphoma, or treated and stabl

  No clinically significant CNS lymphoma, or treated and stable CNS disease in selected cases

• Adequate organ function — heart, liver, kidney, lung — and a

  Adequate organ function — heart, liver, kidney, lung — and acceptable blood counts

• ECOG performance status, typically 0 to 2, depending on prot

  ECOG performance status, typically 0 to 2, depending on protocol

• No active uncontrolled infection, including hepatitis B, hep

  No active uncontrolled infection, including hepatitis B, hepatitis C, or HIV; treated and stable infections may still allow access depending on the protocol

• Sufficient T-cell counts for CAR-T manufacturing and ability

  Sufficient T-cell counts for CAR-T manufacturing and ability to tolerate lymphodepleting chemotherapy

• Travel fitness and a realistic plan for several weeks of in-

  Travel fitness and a realistic plan for several weeks of in-country care

The completeness of records often determines how quickly a meaningful plan can be built. The following are typically requested:

• Latest medical summary and treating oncologist's opinion

  Latest medical summary and treating oncologist's opinion

• Original biopsy and histopathology report confirming follicu

  Original biopsy and histopathology report confirming follicular lymphoma, with grade

• IHC report including CD20, CD19, CD10, BCL2, BCL6, Ki-67, an

  IHC report including CD20, CD19, CD10, BCL2, BCL6, Ki-67, and other relevant markers

• Bone marrow aspiration and biopsy report, where performed

  Bone marrow aspiration and biopsy report, where performed

• Flow cytometry report

  Flow cytometry report

• FISH or molecular report for t(14;18) and other relevant rea

  FISH or molecular report for t(14;18) and other relevant rearrangements

• Recent PET CT report covering neck to thigh, and any prior P

  Recent PET CT report covering neck to thigh, and any prior PET CT for comparison

• CT or MRI reports as relevant

  CT or MRI reports as relevant

• Complete blood count, LDH, beta-2 microglobulin, liver and k

  Complete blood count, LDH, beta-2 microglobulin, liver and kidney function tests

• Hepatitis B, hepatitis C, HIV, and other viral screening res

  Hepatitis B, hepatitis C, HIV, and other viral screening results

• ECG and echocardiogram, especially if anthracycline therapy

  ECG and echocardiogram, especially if anthracycline therapy was given previously

• Detailed treatment history with regimens, cycles, dates, res

  Detailed treatment history with regimens, cycles, dates, response, and reasons for stopping

CancerFax supports follicular lymphoma cases through a structured pathway:

• Case review — diagnosis, grade, prior treatments, current di

  Case review — diagnosis, grade, prior treatments, current disease status, and POD24 history are reviewed against the most relevant treatment options.

• Pathology and biomarker check — IHC, flow cytometry, and mol

  Pathology and biomarker check — IHC, flow cytometry, and molecular reports are checked for CD19 and CD20 expression and any missing investigations are identified before hospital review.

• Hospital and trial matching — the case is shared with approp

  Hospital and trial matching — the case is shared with appropriate Chinese cancer centres running approved CAR-T programmes or clinical trials in follicular lymphoma.

• Bridging strategy — for patients with progressing disease, C

  Bridging strategy — for patients with progressing disease, CancerFax helps coordinate timing between current local treatment and CAR-T or trial admission in China.

• Cost and stay planning — patients receive a clear picture of

  Cost and stay planning — patients receive a clear picture of expected hospital charges, lymphodepletion, infusion, monitoring, accommodation, and follow-up timelines.

• Travel and admission support — visa guidance, interpreter co

  Travel and admission support — visa guidance, interpreter coordination, hospital communication, and admission planning are handled in one pathway.

• Continuity after return home — CancerFax helps maintain comm

  Continuity after return home — CancerFax helps maintain communication between the Chinese treating team and the patient's local oncologist for follow-up scans, lab work, and any further therapy.

This comparison is general. Individual suitability depends on diagnosis details, prior treatments, CD19 and CD20 expression, fitness, and the specific product or trial. The treating oncology team makes the final recommendation.

Advanced lymphoma care, including approved CAR-T therapy and active follicular lymphoma trials, is offered at major academic and specialist centres across China. This includes leading institutions in Beijing, Shanghai, Guangzhou, Tianjin, and other cities, with strong programmes at the Chinese Academy of Medical Sciences and National Cancer Center, Fudan University Shanghai Cancer Center, Renji Hospital, Ruijin Hospital, Peking University Cancer Hospital, Sun Yat-sen University Cancer Center, and several dedicated haematology and cell therapy units. The same therapy category can have different eligibility rules, product choices, admission timelines, and cost structures from one hospital to another. The right centre for a given case depends on diagnosis details, urgency, planned product, and trial availability rather than hospital name alone. CancerFax helps match the case with a centre that fits the clinical situation, not the other way around.

Frequently Asked Questions

Answers to common questions from patients and families.

Structured reference data summarizing key information for this topic.